TWI596095B - Dihydropyridazine-3,5-dione derivatives - Google Patents

Dihydropyridazine-3,5-dione derivatives Download PDF

Info

Publication number
TWI596095B
TWI596095B TW103109058A TW103109058A TWI596095B TW I596095 B TWI596095 B TW I596095B TW 103109058 A TW103109058 A TW 103109058A TW 103109058 A TW103109058 A TW 103109058A TW I596095 B TWI596095 B TW I596095B
Authority
TW
Taiwan
Prior art keywords
group
methyl
trifluoromethyl
phenyl
substituted
Prior art date
Application number
TW103109058A
Other languages
English (en)
Chinese (zh)
Other versions
TW201446756A (zh
Inventor
大竹義仁
岡本直樹
小野芳幸
柏木浩孝
金原篤
原田武雄
堀伸行
村田佳久
橘一生
田中翔太
野村硏一
井出光昭
水口栄作
市田康弘
大友秀一
堀場直
Original Assignee
中外製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中外製藥股份有限公司 filed Critical 中外製藥股份有限公司
Publication of TW201446756A publication Critical patent/TW201446756A/zh
Application granted granted Critical
Publication of TWI596095B publication Critical patent/TWI596095B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Luminescent Compositions (AREA)
TW103109058A 2013-03-13 2014-03-13 Dihydropyridazine-3,5-dione derivatives TWI596095B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013051082 2013-03-13
JP2013132889 2013-06-25

Publications (2)

Publication Number Publication Date
TW201446756A TW201446756A (zh) 2014-12-16
TWI596095B true TWI596095B (zh) 2017-08-21

Family

ID=51536921

Family Applications (2)

Application Number Title Priority Date Filing Date
TW103109058A TWI596095B (zh) 2013-03-13 2014-03-13 Dihydropyridazine-3,5-dione derivatives
TW106123450A TWI683811B (zh) 2013-03-13 2014-03-13 二氫噠嗪-３,５-二酮衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW106123450A TWI683811B (zh) 2013-03-13 2014-03-13 二氫噠嗪-３,５-二酮衍生物

Country Status (29)

Country Link
EP (2) EP3757093A1 (OSRAM)
JP (2) JP5814488B2 (OSRAM)
KR (2) KR101664460B1 (OSRAM)
CN (1) CN105073715B (OSRAM)
AU (1) AU2014230552B2 (OSRAM)
BR (1) BR112015022092B1 (OSRAM)
CA (1) CA2901868C (OSRAM)
CL (1) CL2015002543A1 (OSRAM)
CR (1) CR20150505A (OSRAM)
DK (1) DK2975030T3 (OSRAM)
ES (1) ES2811126T3 (OSRAM)
HR (1) HRP20201211T1 (OSRAM)
HU (1) HUE050577T2 (OSRAM)
IL (1) IL240825B (OSRAM)
LT (1) LT2975030T (OSRAM)
MX (1) MX376532B (OSRAM)
MY (1) MY174269A (OSRAM)
NZ (1) NZ711182A (OSRAM)
PE (1) PE20151535A1 (OSRAM)
PH (1) PH12015501940A1 (OSRAM)
PL (1) PL2975030T3 (OSRAM)
PT (1) PT2975030T (OSRAM)
RS (1) RS60911B1 (OSRAM)
RU (1) RU2662832C2 (OSRAM)
SG (1) SG11201507345RA (OSRAM)
SI (1) SI2975030T1 (OSRAM)
TW (2) TWI596095B (OSRAM)
UA (1) UA118755C2 (OSRAM)
WO (1) WO2014142273A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20201211T1 (hr) * 2013-03-13 2020-11-13 Chugai Seiyaku Kabushiki Kaisha Derivat dihidropiridazin-3,5-diona
EP3928779B1 (en) * 2014-09-12 2024-03-06 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical containing sodium-dependent phosphate transporter inhibitor and phosphorus adsorbent for use in the prevention, treatment or suppression of chronic kidney disease, arteriosclerosis associated with vascular calcification, or ectopic calcification.
WO2018019721A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
WO2018019755A1 (en) 2016-07-26 2018-02-01 Basf Se Herbicidal pyridine compounds
CN110885290A (zh) * 2019-12-16 2020-03-17 阿里生物新材料（常州）有限公司 一种3-氟-2-甲基-4-三氟甲基苯胺盐酸盐的合成方法
CN115734965B (zh) 2020-06-26 2025-05-02 日本农药株式会社 芳基四氢哒嗪衍生物或其盐类、和含有该化合物的杀虫剂及其使用方法
WO2022221182A1 (en) * 2021-04-12 2022-10-20 Jnana Therapeutics Inc. Small molecule inhibitors of mammalian slc34a1 function
KR20240018523A (ko) 2021-06-08 2024-02-13 추가이 세이야쿠 가부시키가이샤 다이하이드로피리다진-3,5-다이온 유도체를 함유하는 제제
AR126060A1 (es) * 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd Método para producir derivado de dihidropiridazin-3,5-diona
WO2023127805A1 (ja) 2021-12-28 2023-07-06 日本農薬株式会社 アリールテトラヒドロピリダジン誘導体又はその塩類及び該化合物を含有する殺虫剤並びにその使用方法
WO2023219127A1 (ja) 2022-05-11 2023-11-16 中外製薬株式会社 嚢胞性疾患を治療または予防するための医薬組成物
CN116217862A (zh) * 2023-03-21 2023-06-06 中国农业科学院农业环境与可持续发展研究所 一种可降解生物膜助剂的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003211381B9 (en) * 2002-02-19 2009-07-30 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
CN1662529A (zh) * 2002-06-19 2005-08-31 默克专利有限公司 作为磷酸二酯酶iv抑制剂的噻唑衍生物
NZ563707A (en) * 2005-05-18 2011-01-28 Array Biopharma Inc Heterocyclic inhibitors of MEK and methods of use thereof
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
EA017900B1 (ru) * 2006-11-03 2013-04-30 Басф Се Способ получения дифторметилпиразолилкарбоксилатов
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
US20130029973A1 (en) 2010-04-28 2013-01-31 Astellas Pharma Inc. Tetrahydrobenzothiophene compound
WO2012006475A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590965B1 (en) * 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
PL2772490T3 (pl) 2011-10-27 2016-11-30 Aminoalkilo-podstawiona pochodna n-tienylobenzamidu
HRP20201211T1 (hr) * 2013-03-13 2020-11-13 Chugai Seiyaku Kabushiki Kaisha Derivat dihidropiridazin-3,5-diona

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011048611A1 (en) * 2009-10-07 2011-04-28 Torrent Pharmaceuticals Limited Novel fused pyridazine derivatives

Also Published As

Publication number Publication date
JP2016040262A (ja) 2016-03-24
EP2975030A1 (en) 2016-01-20
PL2975030T3 (pl) 2021-01-11
PH12015501940B1 (en) 2016-01-11
KR20160119282A (ko) 2016-10-12
PH12015501940A1 (en) 2016-01-11
CN105073715B (zh) 2017-12-01
EP2975030B1 (en) 2020-07-15
JP6420738B2 (ja) 2018-11-07
AU2014230552A1 (en) 2015-08-13
BR112015022092A8 (pt) 2018-01-23
IL240825B (en) 2020-07-30
CR20150505A (es) 2015-10-26
MY174269A (en) 2020-04-01
JP5814488B2 (ja) 2015-11-17
RU2662832C2 (ru) 2018-07-31
MX376532B (es) 2025-03-07
BR112015022092B1 (pt) 2023-04-11
RU2015143507A (ru) 2017-04-19
ES2811126T3 (es) 2021-03-10
EP3757093A1 (en) 2020-12-30
MX2015012537A (es) 2016-02-10
HK1212700A1 (zh) 2016-06-17
KR101664460B1 (ko) 2016-10-10
CA2901868C (en) 2022-05-03
TWI683811B (zh) 2020-02-01
UA118755C2 (uk) 2019-03-11
KR20150127721A (ko) 2015-11-17
WO2014142273A1 (ja) 2014-09-18
PE20151535A1 (es) 2015-10-28
DK2975030T3 (da) 2020-08-31
IL240825A0 (en) 2015-10-29
CL2015002543A1 (es) 2016-02-26
CN105073715A (zh) 2015-11-18
RS60911B1 (sr) 2020-11-30
TW201741304A (zh) 2017-12-01
HUE050577T2 (hu) 2020-12-28
SG11201507345RA (en) 2015-10-29
LT2975030T (lt) 2020-09-25
HRP20201211T1 (hr) 2020-11-13
KR102072268B1 (ko) 2020-01-31
AU2014230552B2 (en) 2017-11-16
BR112015022092A2 (pt) 2017-07-18
TW201446756A (zh) 2014-12-16
PT2975030T (pt) 2020-09-28
EP2975030A4 (en) 2016-08-03
JPWO2014142273A1 (ja) 2017-02-16
SI2975030T1 (sl) 2020-10-30
CA2901868A1 (en) 2014-09-18
NZ711182A (en) 2020-05-29

Similar Documents

Publication Publication Date Title
TWI596095B (zh) Dihydropyridazine-3,5-dione derivatives
CN102548557B (zh) 用于降低β-淀粉状蛋白生成的化合物
CN105939997B (zh) 作为dlk抑制剂的吡唑衍生物及其用途
WO2024083256A1 (zh) pan-KRAS降解剂及其制备方法和应用
CN113321654A (zh) 作为激酶抑制剂的稠合吡啶酮类化合物
CN107072993B (zh) 含有钠依赖性磷酸转运蛋白抑制剂的药物
WO2021190417A1 (zh) 新型氨基嘧啶类egfr抑制剂
CN106661032A (zh) 治疗或预防糖尿病、肥胖症和炎性肠病的1,3‑取代的2‑氨基吲哚衍生物及类似物
CN104640865B (zh) 作为激酶抑制剂的二氢吡咯烷子基-嘧啶
CN108779115B (zh) 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用
WO2023274396A1 (zh) 苯并氮杂环类化合物及其在药物中的应用
HK1212700B (en) Dihydropyridazine-3,5-dione derivative
HK1235279B (zh) 含有钠依赖性磷酸转运蛋白抑制剂的药物
HK1235279A1 (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
RU2811864C1 (ru) Фармацевтическое средство, содержащее ингибитор натрийзависимого переносчика фосфата
WO2025161532A1 (zh) Pde4b抑制剂及其药物组合物和用途